Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multiple Factors Suggest Genzyme Still Faces Problems Related To Cerezyme

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech's decontaminated plant has reopened, but FDA plans to re-inspect the facility. In addition, Genzyme had to discard more in-process Cerezyme than expected and a competitor's investigational drug has received clearance for emergency use by FDA.

You may also be interested in...



Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come

Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come

Shire Files NDA For Gaucher Disease Drug With Data Showing Non-Inferiority To Cerezyme

Lower antibody formation could offer significant differentiation from Genzyme's product.

Related Content

Topics

UsernamePublicRestriction

Register

PS069820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel